Siegfried opens global R&D Center for Drug Substances in Switzerland
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Aims to achieve CDMO sales of US$ 400 million by 2028
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
Subscribe To Our Newsletter & Stay Updated